Brand and Other Names:Alfutral, UroXatral, more...Xatral
- Classes: BPH, Alpha Blockers
Dosing & Uses
Dosage Forms & Strengths
tablet, extended release
Benign Prostatic Hyperplasia (BPH)
10 mg PO qDay taken after same meal
Safety & efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Abdominal pain (1-2%)
Back pain (1-2%)
URT infection (3%)
Upper respiratory infection (3%)
General disorders: Edema
Cardiac disorders: Tachycardia, chest pain, angina pectoris in patients with pre-existing coronary artery disease, atrial fibrillation
Gastrointestinal disorders: Diarrhea
Hepatobiliary disorders: Hepatocellular and cholestatic liver injury (including cases with jaundice leading to drug discontinuation)
Upper respiratory system: Rhinitis
Reproductive system: Priapism
Dermatology: Rash, pruritus, urticaria, angioedema, toxic epidermal necrolysis
Vascular disorders: Flushing
Blood and lymphatic system disorders: Thrombocytopenia
Moderate to severe liver impairment
Coadministration with potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir) or other alpha1-blocking agents
Caution in coronary artery disease, liver disease, symptomatic orthostatic hypotension or coadministration with other drugs that lower blood pressure
May cause syncope (first-dose effect)
Discontinue treatment if angina occurs or worsens
Rule out prostate cancer before initiating therapy (symptoms similar)
Priapism may occur with use
Rule out prostate cancer prior to treatment
Caution with renal impairment (ieg, CrCl <30 mL/min)
Caution with history of prolonged QT syndrome (shown to prolong QT interval)
Intraoperative floppy iris syndrome during cataract surgery reported Advise patient regarding risk of priapism
Do not chew or crush tablets
Not for use as antihypertensive drug
Pregnancy & Lactation
Pregnancy Category: B
Lactation: Not indicated for use in women
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Selective antagonist of postsynaptic alpha-1-adrenoceptors; blockade of adrenoreceptors in the prostate, prostatic capsule, bladder neck and prostatic urethra
Peak Plasma Time: 8 hr
Peak Plasma Concentration: 13.6 ng/mL
AUC: 194 ng.hr/mL
Protein Bound: 82-90%
Vd: 3.2 L/kg
Hepatic P450 enzyme CYP3A4
Half-life: 5-10 hr
Excretion: Feces (69%); urine (24%)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs